Results 21 to 30 of about 4,586,589 (282)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls

Diagnostics, 2023
In June 2021, the US Federal Drug and Food Administration (FDA) granted accelerated approval for the antibody aducanumab and, in January 2023, also for the antibody lecanemab, based on a perceived drug-induced removal of cerebral amyloid-beta as assessed
Poul F. Høilund-Carlsen, Mona-Elisabeth Revheim, Tommaso Costa, Kasper P. Kepp, Rudolph J. Castellani, George Perry, Abass Alavi, Jorge R. Barrio   +7 more
doaj   +1 more source

Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties

, 2022
Cell-penetrating peptides (CPPs) with sequences derived originally from a prion protein (PrP) have been shown to exhibit both anti-prion and anti-amyloid properties particularly against prion proteins and the amyloid-β (Aβ) peptide active in ...
Astrid Gräslund, Österlund, Nicklas,, Gräslund, Astrid,, Nicklas Österlund, Sebastian K. T. S. Wärmländer, Wärmländer, Sebastian K. T. S.,   +5 more
core   +1 more source

Structural Studies of Cystatin B Amyloid Fibre and Oligomer [PDF]

, 2013
Amyloid fibres are characteristic of over 25 degenerative human diseases including Alzheimer’s and Parkinson’s disease. Amyloid fibres are insoluble, highly stable, ordered cross-β sheet structures, which form as a result of conformational change and ...
Davis, Peter J.
core   +5 more sources

Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease [PDF]

BMC Neurology, 2014
High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies.These therapies are based on the
Castello, Michael A, Jeppson, John David, Soriano, Salvador   +2 more
openaire   +2 more sources

Cerebral amyloid angiopathy : new insights from transgenic mice [PDF]

, 2004
Cerebral amyloid angiopathy (CAA) is characterized by the deposition of congophilic material within the walls of small to medium-sized blood vessels of the brain and leptomeninges.
Herzig, Martin C.
core   +1 more source

Fibril fragmentation in amyloid assembly and cytotoxicity: When size matters [PDF]

, 2010
Amyloid assemblies are associated with several debilitating human disorders. Understanding the intra- and extracellular assembly of normally soluble proteins and peptides into amyloid aggregates and how they disrupt normal cellular functions is therefore
Xue, Wei-Feng, Hellewell, Andrew L., Hewitt, Eric W., Radford, Sheena E., Eric W. Hewitt, Andrew L. Hellewell, Wei-Feng Xue, Sheena E. Radford   +7 more
core   +1 more source

Anti-amyloid treatment is broadly effective in neuronopathic mucopolysaccharidoses and synergizes with gene therapy in MPS-IIIA [PDF]

: Mucopolysaccharidoses (MPSs) are childhood diseases caused by inherited deficiencies in glycosaminoglycans degradation. Most MPSs involve neurodegeneration, which to date is untreatable.
Ibrar, Siddique, Thomas, Schrader, Claudia, Perna, Borzacchiello L., Antonio, Monaco, Sorrentino N. C., Alessandro, Fraldi, Laura, Galiano, Marie, Khijniak, Perna C., Pasquale, Piccolo, Marianna, Giaccio, Rubino R., Pan X., Galiano L., Killa D., Marcello, Marotta, Luigi, Borzacchiello, Pshezhetsky, Alexey V., Klarner F. -G., Siddique I., Pshezhetsky A. V., Riccardo, Rubino, Andrea, Parente, Fraldi A., Giaccio M., Dennis, Killa, Frank-Gerrit, Klärner, Cristina, Sorrentino Nicolina, Parente A., Marotta M., Schrader T., Piccolo P., Gal, Bitan, Khijniak M., Bitan G., Monaco A., Xuefang, Pan   +37 more
core   +2 more sources

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization

, 2013
Inflammatory processes are important in the pathogenesis of Alzheimer's disease and in response to amyloid-β immunotherapy. We investigated the expression of multiple inflammatory markers in the brains of 28 non-immunized patients with Alzheimer's ...
Cheaveau, M., Morgan, William, Cheaveau, Matthew, Boche, Delphine, Bharambe, V., Holmes, C., Love, S., Nicoll, James A R, Harris, Scott, Bharambe, Viraj, Neal, James W, Love, Seth, Nicoll, J.A.R., Zotova, E., Boche, D., Morgan, W., Neal, J.W., Holmes, Clive, Zotova, Elina   +18 more
core   +1 more source

Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models.

PLoS ONE, 2008
Alzheimer's disease is a neurodegenerative disorder typified by the accumulation of a small protein, beta-amyloid, which aggregates and is the primary component of amyloid plaques.
Scott B Raymond, Lisa H Treat, Jonathan D Dewey, Nathan J McDannold, Kullervo Hynynen, Brian J Bacskai   +5 more
doaj   +1 more source

Clinical trials of new drugs for Alzheimer disease

Journal of Biomedical Science, 2020
Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent.
Li-Kai Huang, Shu-Ping Chao, Chaur-Jong Hu   +2 more
doaj   +1 more source